ArticleOphthalmology science2026
Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial.
Tong Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.